High-risk medications and their related claims are among the most financially and clinically significant exposures facing the practice of medicine today—and the stakes are hard to ignore. Over the past two decades, verdicts and settlements tied to alleged misuse of synthetic oxytocin (Pitocin) have reached extraordinary levels, exceeding $950 million, often reflecting the projected lifetime care needs of children with severe neurologic injury.
| Notable Verdicts & Settlements (2005–2025)¹ | |
| $951 Million (Utah, 2025) | A default judgment against Steward Health Care. The case involved "newly oriented" nurses administering high Pitocin levels for hours despite clear fetal distress and an unresponsive on-call physician. |
| $37 Million (New Jersey, 2024) | A jury verdict for a child born with cerebral palsy attributed to negligent Pitocin administration during childbirth. |
| $25.4 Million (Missouri, 2022) | A record-setting verdict in Kansas City for an infant who suffered brain injury due to excessive Pitocin and lack of resident supervision. |
| $10 Million (Wisconsin, 2025) | A jury awarded this amount after determining Pitocin was used to speed labor without the mother's informed consent, leading to permanent brain damage. |
| 5.7 Million (California 2021) | A settlement following allegations that the hospital violated its own policies by continuing Pitocin administration despite clear signs of tachysystole (more than five contractions in 10 minutes averaged over 30 minutes) shortly after the fourth increase in Pitocin, leading to severe brain damage. |
| $4.5 Million (Minnesota, 2006) | A settlement following inappropriate use of Pitocin and a failure to perform a timely emergency C-section. |
Legal Exposures
According to resources, common legal arguments in these cases include:²
- Lack of Informed Consent: Using the drug to hasten labor without advising the mother of potential risks.
- Failure to Monitor: Not properly interpreting fetal heart rate tracings (non-reassuring strips) while continuing Pitocin.
- Overstimulation (Tachysystole): Administering doses that cause contractions to be either too frequent or too strong—preventing the baby
from receiving adequate oxygen. - Delayed Intervention: Failing to stop the drug or perform a C-section once distress was evident.
From a risk management perspective, these cases consistently center on a handful of recurring themes: inadequate understanding or communication of management options, excessive or poorly titrated dosing, and failure to discontinue the medication in the presence of evolving fetal distress. The resulting allegations frequently involve hypoxic-ischemic encephalopathy (HIE) and cerebral palsy—outcomes that carry profound human and legal consequences. We are highlighting this topic because these patterns persist, and targeted awareness and practice refinement can meaningfully reduce both patient harm and liability exposure.
The American College of Obstetrics and Gynecology (ACOG) Committee Opinion on Informed Consent and Shared Decision Making noted,“ . . . [while some] informed consent challenges are universal to medicine . . . other challenges arise more commonly in the practice of obstetrics and gynecology than in other specialty areas.”³
Placing a spotlight on high-risk medications, like Pitocin, is an essential effort to improve patient outcomes and support clearer clinical decision-making. In obstetrics, where consent discussions often occur in information-dense and emotionally charged moments, a more effective approach is starting these conversations early in the antenatal period—and reinforcing the discussion throughout the course of care.
Best practices include modeling ongoing communication, consent re-revaluation, and shared decision-making during discussions addressing the indications for Pitocin use; the risks of overuse such as uterine hyperstimulation (tachysystole); the alternatives to Pitocin use; or the option to refuse augmentation/induction.³
- Encourage patient sharing of values, preferences, and concerns—to enhance informed consent/informed refusal discussions—documenting that decision process fully. Encourage questions and concerns to be raised promptly. Provide written materials or decision aids to reinforce key points.³
- Ensure the patient can understand the discussion,3,4 do not rely on family, extended family members or caregivers—employ qualified translation services, if needed.
- Employ the teach-back method—assess the patients’ retention and understanding of medication usage by asking them to repeat their understanding of the information back to the health care provider.4
- Reconfirm consent or refusal at key decision points (e.g., when fetal distress is suspected or confirmed).5
- Engage the patient in real-time decision-making by discussing the rationale for increasing or decreasing Pitocin and when operative or cesarean delivery becomes an option in the setting of fetal distress.6
Navigating the process of obtaining informed consent and informed refusal, and incorporating shared decision-making with every patient and their unique circumstances is a challenge. Each provider must develop their own approach, pattern, and timing. Approaching the informed consent and informed refusal process by including the conversations related to the management of high-risk medication use not only supports safer care, but also demonstrates a deliberate, patient-centered process that is consistently reflected in the medical record7—one of the most critical factors in the defense of the use of high-risk medications, like related claims
Deanna Spounias, Pharm. D. is a Senior Risk Management and Patient Safety Specialist. Questions or comments related to this article should be directed to DSpounias@CAPphysicians.com.
References
1Lawsuit Information Center. “Pitocin Overdose Birth Injury Lawsuit.” Accessed March 2026.
https://www.lawsuit-information-center.com/pitocin-overdose-birth-injur…
²LexisNexis®“Verdict & Settlement Analyzer.” Accessed April 2026. https://www.lexisnexis.com/en-us/products/verdict-and-settlement-analyz…
³American College of Obstetricians and Gynecologists. “Informed Consent and Shared Decision Making in Obstetrics and Gynecology.” Committee Opinion No. 819. February 2021. Reaffirmed 2025. Accessed April 2026. https://www.acog.org/clinical/clinical-guidance/committee-opinion/artic…
4American College of Obstetricians and Gynecologists. “Improving Medication Safety.” Committee Opinion No. 531. August 2012. Reaffirmed 2016. Accessed April 2026. https://www.acog.org/clinical/clinical-guidance/committee-opinion/artic…
5ECRI. “Ask ECRI Is Written Informed Consent Recommended for High-Alert Medications Used during Labor and Delivery.” Accessed April 2026. https://members.ecri.org/guidance/hsrm-ask-ecri-is-written-informed-con…
6American College of Obstetricians and Gynecologists. “Refusal of Medically Recommended Treatment During Pregnancy.” Committee Opinion No. 664. June 2016. Reaffirmed 2025. Accessed March 2026. https://www.acog.org/clinical/clinical-guidance/committee-opinion/artic…
7United States. Code of Federal Regulations. Title 42, Chapter IV, Subchapter G, Part 482, Subpart C, Sec. 482.24. “Consent documentation.” Accessed April 2026. https://www.ecfr.gov/current/title-42/chapter-IV/subchapter-G/part-482/…